Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alicaforsen - Atlantic Healthcare

Drug Profile

Alicaforsen - Atlantic Healthcare

Alternative Names: Alicaforsen enema; Alicaforsen sodium; AP 1007; AP 1431; AP 1450; AP 1451; Camligo; ISIS 2302

Latest Information Update: 07 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Isis Pharmaceuticals
  • Developer Atlantic Healthcare
  • Class Anti-inflammatories; Antipsoriatics; Antisense oligonucleotides; Thionucleotides
  • Mechanism of Action Immunosuppressants; Intercellular adhesion molecule 1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pouchitis
  • New Molecular Entity Yes
  • Available For Licensing Yes - Crohn's disease; Pouchitis; Ulcerative colitis

Highest Development Phases

  • Preregistration Pouchitis
  • Phase III Ulcerative colitis
  • Preclinical Crohn's disease
  • Discontinued Asthma; Inflammation; Psoriasis; Renal transplant rejection; Rheumatoid arthritis

Most Recent Events

  • 31 Jul 2019 Atleantic Healthcare plans to meet the US FDA and EMA to discuss the pathway to regulatory approval
  • 31 Jul 2019 Primary efficacy and adverse events data from a phase III trial in Pouchitis released by Atlantic healthcare
  • 29 Oct 2018 Atlantic Healthcare completes a phase III trial in Pouchitis in Belgium, Canada, England, France, Ireland, Israel, Italy, Netherlands, Switzerland, United Kingdom, USA (NCT02525523)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top